Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military setting R327G to be evaluated as a potential replacement for traditional antimicrobial dressings and topicals used in the military setting SYDNEY, July 16, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company), the Company developing a new class of synthetic anti-infectives, today announced it has been awarded $2 million in grant funding from the U.S. Department of Defense in recognition of RECCE® 327 Gel (R327G) as a topical treatment for burn wound infections. "We are honored by the U.S. Department of Defense's decision to award grant funding for R327G, as it underscores our commitment to advancing medical solutions critical to military personnel," said James Graham, Chief Executive Officer of Recce Pharmaceuticals. "This recognition is a testament to our technology's unique profile and high-quality R&D. We look forward to working closely with the U.S. Department of Defense to progress our research efforts and fulfill our commitment to improving global health outcomes." The grant funding from the U.S. Department of Defense Congressionally Directed Medical Research Programs (CDMRP) will enable the Company to accelerate the development of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections and minimize the onset of bacteremia complications, such as sepsis. The project aims to establish the potential for R327G products for use in ...